Amphastar Pharmaceuticals (AMPH) Operating Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Operating Expenses history runs 14 years deep, the most recent figure standing at $56.7 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 18.21% year-over-year to $56.7 million; the TTM figure through Mar 2026 stood at $219.0 million (up 25.64% YoY), while the FY2025 annual figure was $215.7 million, up 28.03% from the prior year.
• Operating Expenses was $56.7 million for Q1 2026 at Amphastar Pharmaceuticals, up from $50.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $73.3 million in Q3 2025 to a low of $33.3 million in Q4 2022.
• Historically, Operating Expenses has averaged $43.0 million across 5 years, with a median of $40.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses declined 6.98% in 2023, then jumped 63.34% in 2025.
• A 5-year view of Operating Expenses shows it stood at $33.3 million in 2022, then grew by 26.47% to $42.2 million in 2023, then fell by 1.56% to $41.5 million in 2024, then rose by 20.62% to $50.1 million in 2025, then climbed by 13.24% to $56.7 million in 2026.
• The last three Operating Expenses figures came in at $56.7 million (Q1 2026), $50.1 million (Q4 2025), and $73.3 million (Q3 2025), per Business Quant data.